Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group (RHHBY) – Avastin® , Rituxan® , and Herceptin® that collectively represented...
Read More »
Posts Tagged ‘ Eli Lilly & Co ’
Allos Therapeutics
ALTH
AMAG
AMAG Pharmaceuticals
American Society of Clinical Oncology
Amgen
AMGN
Amicus Therapeutics
AMLN
ASCO
BIIB
Biogen Idec
biotech
biotechnology
BMY
cancer
CELG
Celgene
CEPH
Cephalon
Cougar Biotechnology
CYCC
Cyclacel Pharmaceuticals
Dendreon
DNDN
Eli Lilly & Co
FOLD
genentech
GENZ
GlaxoSmithKline
GSK
HGSI
life sciences
LLY
OSIR
Osiris Therapeutics
PFE
Pfizer
prostate cancer
Provenge
roche
Seattle Genetics
SGEN
SNY
Soligenix
Monoclonal Antibody Companies Command Premiums
Five Key Factors Weighing on Dendreon
Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration approval for Provenge® , the first active immunotherapy approved for the treatment of cancer in the U.S. Today, shares of Dendreon traded as low as $28.01,...
Read More »
Three Recent Biotechnology Activist Wins by Carl Icahn
Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset divestiture and other...
Read More »







